Skip to main content
Erschienen in: Cancer Causes & Control 5/2017

02.03.2017 | Original paper

Lifetime number of ovulatory cycles and epithelial ovarian cancer risk in African American women

verfasst von: Lauren C. Peres, Patricia G. Moorman, Anthony J. Alberg, Elisa V. Bandera, Jill Barnholtz-Sloan, Melissa Bondy, Michele L. Cote, Ellen Funkhouser, Edward S. Peters, Ann G. Schwartz, Paul D. Terry, Sarah E. Abbott, Fabian Camacho, Frances Wang, Joellen M. Schildkraut

Erschienen in: Cancer Causes & Control | Ausgabe 5/2017

Einloggen, um Zugang zu erhalten

Abstract

Purpose

Incessant ovulation has been consistently linked to epithelial ovarian cancer (EOC). Although reproductive characteristics differ substantially by race, the association between incessant ovulation and EOC has been evaluated only in populations of predominantly white women. In the present study, we examined the association between lifetime number of ovulatory cycles (LOCs) and EOC risk among African American (AA) women.

Methods

We used data from 534 cases and 722 controls enrolled in the African American Cancer Epidemiology Study. LOCs were determined using the standard method, with modifications to include episodes of irregular or missed periods. Multivariable logistic regression was used to estimate odds ratios (ORs) and 95% confidence intervals (CIs) for the association between LOCs and EOC risk overall and by age, while adjusting for appropriate confounders.

Results

The mean number of LOCs was 378.2 ± 105.8 for cases and 346.4 ± 117.3 for controls. Women in the highest tertile of LOCs had 59% higher odds of EOC compared to women in the lowest tertile (OR = 1.59; 95% CI = 1.15–2.20). When examining this relationship by age, the positive association with EOC was stronger among women <50 years of age (OR for highest vs. lowest tertile = 2.61; 95% CI = 1.15–5.94), followed by women aged 50–60 years (OR = 2.27; 95% CI = 1.30–3.94). Yet, no association was present among women aged >60 years (OR = 0.79; 95% CI = 0.45–1.40).

Conclusions

In a population of AA women, we observed a positive association between LOCs and EOC risk, providing further support for the hypothesis that incessant ovulation contributes to the etiology of EOC.
Literatur
1.
Zurück zum Zitat Fathalla MF (1971) Incessant ovulation—a factor in ovarian neoplasia? The Lancet 2:163CrossRef Fathalla MF (1971) Incessant ovulation—a factor in ovarian neoplasia? The Lancet 2:163CrossRef
2.
Zurück zum Zitat Fathalla MF (2013) Incessant ovulation and ovarian cancer—a hypothesis re-visited. Facts Views Vis ObGyn 5:292–297PubMedPubMedCentral Fathalla MF (2013) Incessant ovulation and ovarian cancer—a hypothesis re-visited. Facts Views Vis ObGyn 5:292–297PubMedPubMedCentral
3.
Zurück zum Zitat Fleming JS, Beaugie CR, Haviv I et al (2006) Incessant ovulation, inflammation and epithelial ovarian carcinogenesis: revisiting old hypotheses. Mol Cell Endocrinol 247:4–21CrossRefPubMed Fleming JS, Beaugie CR, Haviv I et al (2006) Incessant ovulation, inflammation and epithelial ovarian carcinogenesis: revisiting old hypotheses. Mol Cell Endocrinol 247:4–21CrossRefPubMed
4.
Zurück zum Zitat Cramer DW, Welch WR (1983) Determinants of ovarian cancer risk. II. Inferences regarding pathogenesis. J Natl Cancer Inst 71:717–721PubMed Cramer DW, Welch WR (1983) Determinants of ovarian cancer risk. II. Inferences regarding pathogenesis. J Natl Cancer Inst 71:717–721PubMed
5.
Zurück zum Zitat Risch HA (1998) Hormonal etiology of epithelial ovarian cancer, with a hypothesis concerning the role of androgens and progesterone. J Natl Cancer Inst 90:1774–1786CrossRefPubMed Risch HA (1998) Hormonal etiology of epithelial ovarian cancer, with a hypothesis concerning the role of androgens and progesterone. J Natl Cancer Inst 90:1774–1786CrossRefPubMed
6.
7.
Zurück zum Zitat Ness RB, Cottreau C (1999) Possible role of ovarian epithelial inflammation in ovarian cancer. J Natl Cancer Inst 91:1459–1467CrossRefPubMed Ness RB, Cottreau C (1999) Possible role of ovarian epithelial inflammation in ovarian cancer. J Natl Cancer Inst 91:1459–1467CrossRefPubMed
8.
Zurück zum Zitat Tung K-H, Goodman MT, Wu AH et al (2003) Reproductive factors and epithelial ovarian cancer risk by histologic type: a multiethnic case–control study. Am J Epidemiol 158:629–638CrossRefPubMed Tung K-H, Goodman MT, Wu AH et al (2003) Reproductive factors and epithelial ovarian cancer risk by histologic type: a multiethnic case–control study. Am J Epidemiol 158:629–638CrossRefPubMed
9.
Zurück zum Zitat Schildkraut JM, Bastos E, Berchuck A (1997) Relationship between lifetime ovulatory cycles and overexpression of mutant p53 in epithelial ovarian cancer. J Natl Cancer Inst 89:932–938CrossRefPubMed Schildkraut JM, Bastos E, Berchuck A (1997) Relationship between lifetime ovulatory cycles and overexpression of mutant p53 in epithelial ovarian cancer. J Natl Cancer Inst 89:932–938CrossRefPubMed
10.
Zurück zum Zitat Terry KL, Titus-Ernstoff L, McKolanis JR et al (2007) Incessant ovulation, mucin 1 immunity, and risk for ovarian cancer. Cancer Epidemiol Biomarkers Prev 16:30–35CrossRefPubMed Terry KL, Titus-Ernstoff L, McKolanis JR et al (2007) Incessant ovulation, mucin 1 immunity, and risk for ovarian cancer. Cancer Epidemiol Biomarkers Prev 16:30–35CrossRefPubMed
11.
Zurück zum Zitat Moorman PG, Schildkraut JM, Calingaert B et al (2002) Ovulation and ovarian cancer: a comparison of two methods for calculating lifetime ovulatory cycles (United States). Cancer Causes Control 13:807–811CrossRefPubMed Moorman PG, Schildkraut JM, Calingaert B et al (2002) Ovulation and ovarian cancer: a comparison of two methods for calculating lifetime ovulatory cycles (United States). Cancer Causes Control 13:807–811CrossRefPubMed
12.
Zurück zum Zitat Purdie DM, Bain CJ, Siskind V et al (2003) Ovulation and risk of epithelial ovarian cancer. Int J Cancer 104:228–232CrossRefPubMed Purdie DM, Bain CJ, Siskind V et al (2003) Ovulation and risk of epithelial ovarian cancer. Int J Cancer 104:228–232CrossRefPubMed
13.
Zurück zum Zitat Webb PM, Green A, Cummings MC et al (1998) Relationship between number of ovulatory cycles and accumulation of mutant p53 in epithelial ovarian cancer. J Natl Cancer Inst 90:1729–1734CrossRefPubMed Webb PM, Green A, Cummings MC et al (1998) Relationship between number of ovulatory cycles and accumulation of mutant p53 in epithelial ovarian cancer. J Natl Cancer Inst 90:1729–1734CrossRefPubMed
14.
Zurück zum Zitat Gwinn ML, Lee NC, Rhodes PH et al (1990) Pregnancy, breastfeeding, and oral contraceptives and the risk of epithelial ovarian cancer. J Clin Epidemiol 43:559–568CrossRefPubMed Gwinn ML, Lee NC, Rhodes PH et al (1990) Pregnancy, breastfeeding, and oral contraceptives and the risk of epithelial ovarian cancer. J Clin Epidemiol 43:559–568CrossRefPubMed
15.
Zurück zum Zitat Titus-Ernstoff L, Perez K, Cramer DW et al (2001) Menstrual and reproductive factors in relation to ovarian cancer risk. Br J Cancer 84:714–721CrossRefPubMedPubMedCentral Titus-Ernstoff L, Perez K, Cramer DW et al (2001) Menstrual and reproductive factors in relation to ovarian cancer risk. Br J Cancer 84:714–721CrossRefPubMedPubMedCentral
16.
Zurück zum Zitat Luan N, Wu Q, Gong T et al (2013) Breastfeeding and ovarian cancer risk†¯: a meta-analysis of epidemiologic studies. Am J Clin Nutr 98:1020–1031CrossRefPubMedPubMedCentral Luan N, Wu Q, Gong T et al (2013) Breastfeeding and ovarian cancer risk†¯: a meta-analysis of epidemiologic studies. Am J Clin Nutr 98:1020–1031CrossRefPubMedPubMedCentral
17.
Zurück zum Zitat Whittmore AS, Harris R, Itnyre J, Group COC (1992) Characteristics relating to ovarian cancer risk: collaborative analysis of 12 US case–control studies. II. Invasive epithelial ovarian cancers in white women. Am J Epidemiol 136:1184–1203CrossRef Whittmore AS, Harris R, Itnyre J, Group COC (1992) Characteristics relating to ovarian cancer risk: collaborative analysis of 12 US case–control studies. II. Invasive epithelial ovarian cancers in white women. Am J Epidemiol 136:1184–1203CrossRef
18.
Zurück zum Zitat Siskind V, Green A, Bain C, Purdie D (2000) Beyond ovulation: oral contraceptives and epithelial ovarian cancer. Epidemiology 11:106–110CrossRefPubMed Siskind V, Green A, Bain C, Purdie D (2000) Beyond ovulation: oral contraceptives and epithelial ovarian cancer. Epidemiology 11:106–110CrossRefPubMed
19.
20.
Zurück zum Zitat Chumlea WC, Schubert CM, Roche AF et al (2003) Age at menarche and racial comparisons in US girls. Pediatrics 111:110–113CrossRefPubMed Chumlea WC, Schubert CM, Roche AF et al (2003) Age at menarche and racial comparisons in US girls. Pediatrics 111:110–113CrossRefPubMed
22.
Zurück zum Zitat Schildkraut J, Abbott S, Alberg A, et al (2016) Association between body powder use and ovarian cancer: the African American Cancer Epidemiology Study (AACES). Cancer Epidemiol Biomarkers Prev 25:1411–1417CrossRefPubMed Schildkraut J, Abbott S, Alberg A, et al (2016) Association between body powder use and ovarian cancer: the African American Cancer Epidemiology Study (AACES). Cancer Epidemiol Biomarkers Prev 25:1411–1417CrossRefPubMed
23.
Zurück zum Zitat Peres LC, Camacho F, Abbott SE et al (2016) Analgesic medication use and risk of epithelial ovarian cancer in African American women. Br J Cancer 114:819–825CrossRefPubMedPubMedCentral Peres LC, Camacho F, Abbott SE et al (2016) Analgesic medication use and risk of epithelial ovarian cancer in African American women. Br J Cancer 114:819–825CrossRefPubMedPubMedCentral
24.
Zurück zum Zitat Tung KH, Wilkens LR, Wu AH et al (2005) Effect of anovulation factors on pre- and postmenopausal ovarian cancer risk: revisiting the incessant ovulation hypothesis. Am J Epidemiol 161:321–329CrossRefPubMed Tung KH, Wilkens LR, Wu AH et al (2005) Effect of anovulation factors on pre- and postmenopausal ovarian cancer risk: revisiting the incessant ovulation hypothesis. Am J Epidemiol 161:321–329CrossRefPubMed
25.
Zurück zum Zitat Negri E, Franceschi S, Tzonou A et al (1991) Pooled analysis of 3 European case–control studies: I. Reproductive factors and risk of epithelial ovarian cancer. Int J Cancer 49:50–56CrossRefPubMed Negri E, Franceschi S, Tzonou A et al (1991) Pooled analysis of 3 European case–control studies: I. Reproductive factors and risk of epithelial ovarian cancer. Int J Cancer 49:50–56CrossRefPubMed
26.
Zurück zum Zitat Beral V, Doll R, Hermon C et al (2008) Ovarian cancer and oral contraceptives: collaborative reanalysis of data from 45 epidemiological studies including 23,257 women with ovarian cancer and 87,303 controls. Lancet 371:303–314CrossRefPubMed Beral V, Doll R, Hermon C et al (2008) Ovarian cancer and oral contraceptives: collaborative reanalysis of data from 45 epidemiological studies including 23,257 women with ovarian cancer and 87,303 controls. Lancet 371:303–314CrossRefPubMed
28.
Zurück zum Zitat Burger HG, Dudley EC, Robertson DM, Dennerstein L (2002) Hormonal changes in the menopause transition. Recent Prog Horm Res 57:257–275CrossRefPubMed Burger HG, Dudley EC, Robertson DM, Dennerstein L (2002) Hormonal changes in the menopause transition. Recent Prog Horm Res 57:257–275CrossRefPubMed
29.
Zurück zum Zitat Gnagy S, Ming EE, Devesa S et al (2000) Declining ovarian cancer rates in US women in relation to parity and oral contraceptive use. Epidemiology 11:102–105CrossRefPubMed Gnagy S, Ming EE, Devesa S et al (2000) Declining ovarian cancer rates in US women in relation to parity and oral contraceptive use. Epidemiology 11:102–105CrossRefPubMed
30.
Zurück zum Zitat Shih I-M, Kurman RJ (2004) Ovarian tumorigenesis: a proposed model based on morphological and molecular genetic analysis. Am J Pathol 164:1511–1518CrossRefPubMedPubMedCentral Shih I-M, Kurman RJ (2004) Ovarian tumorigenesis: a proposed model based on morphological and molecular genetic analysis. Am J Pathol 164:1511–1518CrossRefPubMedPubMedCentral
31.
Zurück zum Zitat Jukic AMZ, Weinberg CR, Wilcox AJ et al (2008) Accuracy of reporting of menstrual cycle length. Am J Epidemiol 167:25–33CrossRefPubMed Jukic AMZ, Weinberg CR, Wilcox AJ et al (2008) Accuracy of reporting of menstrual cycle length. Am J Epidemiol 167:25–33CrossRefPubMed
32.
Zurück zum Zitat Bosetti C, Tavani A, Negri E et al (2001) Reliability of data on medical conditions, menstrual and reproductive history provided by hospital controls. J Clin Epidemiol 54:902–906CrossRefPubMed Bosetti C, Tavani A, Negri E et al (2001) Reliability of data on medical conditions, menstrual and reproductive history provided by hospital controls. J Clin Epidemiol 54:902–906CrossRefPubMed
33.
Zurück zum Zitat Mihm M, Gangooly S, Muttukrishna S (2011) The normal menstrual cycle in women. Anim Reprod Sci 124:229–236CrossRefPubMed Mihm M, Gangooly S, Muttukrishna S (2011) The normal menstrual cycle in women. Anim Reprod Sci 124:229–236CrossRefPubMed
34.
Zurück zum Zitat Yang HP, Murphy KR, Pfeiffer RM et al (2016) Lifetime number of ovulatory cycles and risks of ovarian and endometrial cancer among postmenopausal women. Am J Epidemiol 183:800–814CrossRefPubMed Yang HP, Murphy KR, Pfeiffer RM et al (2016) Lifetime number of ovulatory cycles and risks of ovarian and endometrial cancer among postmenopausal women. Am J Epidemiol 183:800–814CrossRefPubMed
Metadaten
Titel
Lifetime number of ovulatory cycles and epithelial ovarian cancer risk in African American women
verfasst von
Lauren C. Peres
Patricia G. Moorman
Anthony J. Alberg
Elisa V. Bandera
Jill Barnholtz-Sloan
Melissa Bondy
Michele L. Cote
Ellen Funkhouser
Edward S. Peters
Ann G. Schwartz
Paul D. Terry
Sarah E. Abbott
Fabian Camacho
Frances Wang
Joellen M. Schildkraut
Publikationsdatum
02.03.2017
Verlag
Springer International Publishing
Erschienen in
Cancer Causes & Control / Ausgabe 5/2017
Print ISSN: 0957-5243
Elektronische ISSN: 1573-7225
DOI
https://doi.org/10.1007/s10552-017-0853-7

Weitere Artikel der Ausgabe 5/2017

Cancer Causes & Control 5/2017 Zur Ausgabe

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

25.04.2024 NSCLC Nachrichten

Das Risiko für Rezidiv oder Tod von Patienten und Patientinnen mit reseziertem ALK-positivem NSCLC ist unter einer adjuvanten Therapie mit dem Tyrosinkinase-Inhibitor Alectinib signifikant geringer als unter platinbasierter Chemotherapie.

Bei Senioren mit Prostatakarzinom auf Anämie achten!

24.04.2024 DGIM 2024 Nachrichten

Patienten, die zur Behandlung ihres Prostatakarzinoms eine Androgendeprivationstherapie erhalten, entwickeln nicht selten eine Anämie. Wer ältere Patienten internistisch mitbetreut, sollte auf diese Nebenwirkung achten.

ICI-Therapie in der Schwangerschaft wird gut toleriert

Müssen sich Schwangere einer Krebstherapie unterziehen, rufen Immuncheckpointinhibitoren offenbar nicht mehr unerwünschte Wirkungen hervor als andere Mittel gegen Krebs.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.